(NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced initiation of a Phase 1 study of SCY-770, a first-in-class, potent and direct ...

Autosomal dominant polycystic kidney disease (ADPKD) causes cysts to grow in your kidneys. It's one of the most common genetic kidney diseases. ADPKD is inherited. It's caused by a change, or mutation ...

Add Yahoo as a preferred source to see more of our stories on Google. Sep. 3—(StatePoint) This article is sponsored by Otsuka America Pharmaceutical, Inc. Each year, September 4 marks Polycystic ...

ART5 is designed to address the most common root cause of ADPKD by targeting PKD1, potentially restoring PC1 production in approximately 85% of ...

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited condition that can lead to kidney failure. Being able to accurately predict how the disease will progress is very ...

Major complications occur in 7.0% of patients undergoing nephrectomy with a diagnosis of autosomal dominant polycystic kidney disease (ADPKD), according to a study published online Dec. 17 in Urology ...

SAN DIEGO, Sept. 20, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ...

Developing new gene therapies for autosomal dominant polycystic kidney disease (ADPKD) is still a challenge to date. A group of researchers from the Johns Hopkins Medicine in Baltimore has presented ...

—Mayo Clinic researchers recently studied an algorithm based on artificial intelligence (AI) for measuring magnetic resonance-derived total kidney volume in autosomal dominant polycystic kidney ...

Findings support the importance of quality-of-life assessment of patients with ADPKD. Disease-specific instruments best capture the burden of autosomal dominant polycystic kidney disease (ADPKD) on ...